StockData
Kalaris Therapeutics, Inc. logo

Kalaris Therapeutics, Inc. (KLRS) stock

KLRSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.37−0.06 (-4.20%)

Close on Nov 18, 2026Market cap $32.61MP/E –Yield –

Kalaris Therapeutics operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Kalaris Therapeutics's operating income for the twelve months ending Jun 30, 2026 was -$47.76M. For fiscal 2025 it was -$46.15M. The highest annual figure on record is -$26.70M in fiscal 2019.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$46.15M–
FY2024Dec 31, 2024-$51.73M–
FY2023Dec 31, 2023-$199.90M–
FY2022Dec 31, 2022-$171.20M–
FY2021Dec 31, 2021-$169.82M–
FY2020Dec 31, 2020-$71.31M–
FY2019Dec 31, 2019-$26.70M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$12.39M–
Q1 FY2026Mar 31, 2026-$11.83M–
Q4 FY2025Dec 31, 2025-$10.80M–
Q3 FY2025Sep 30, 2025-$12.74M–
Q2 FY2025Jun 30, 2025-$12.26M–
Q1 FY2025Mar 31, 2025-$10.35M–
Q4 FY2024Dec 31, 2024-$7.13M–
Q3 FY2024Sep 30, 2024-$37.85M–
Q2 FY2024Jun 30, 2024-$4.19M–
Q1 FY2024Mar 31, 2024-$2.56M–
Q4 FY2023Dec 31, 2023-$62.41M–
Q3 FY2023Sep 30, 2023-$46.96M–
Q2 FY2023Jun 30, 2023-$47.30M–
Q1 FY2023Mar 31, 2023-$43.23M–
Q4 FY2022Dec 31, 2022-$40.43M–
Q3 FY2022Sep 30, 2022-$42.95M–
Q2 FY2022Jun 30, 2022-$44.62M–
Q1 FY2022Mar 31, 2022-$43.19M–
Q4 FY2021Dec 31, 2021-$55.80M–
Q3 FY2021Sep 30, 2021-$45.50M–
Q2 FY2021Jun 30, 2021-$37.66M–
Q1 FY2021Mar 31, 2021-$30.86M–
Q4 FY2020Dec 31, 2020-$25.42M–
Q3 FY2020Sep 30, 2020-$23.90M–
Q2 FY2020Jun 30, 2020-$12.15M–
Q1 FY2020Mar 31, 2020-$9.84M–
Q4 FY2019Dec 31, 2019-$9.51M–
Q3 FY2019Sep 30, 2019-$8.48M–
Q2 FY2019Jun 30, 2019-$5.95M–

More Kalaris Therapeutics figures

See a number that looks wrong?